185 related articles for article (PubMed ID: 34720077)
21. Design, Synthesis, and in-
Abdalsatar Abdalrazaq N; Ezleen Binti Kamarulzaman E
Arch Razi Inst; 2022 Apr; 77(2):843-852. PubMed ID: 36284983
[TBL] [Abstract][Full Text] [Related]
22. Discovering key residues of dengue virus NS2b-NS3-protease: New binding sites for antiviral inhibitors design.
Aguilera-Pesantes D; Robayo LE; Méndez PE; Mollocana D; Marrero-Ponce Y; Torres FJ; Méndez MA
Biochem Biophys Res Commun; 2017 Oct; 492(4):631-642. PubMed ID: 28343993
[TBL] [Abstract][Full Text] [Related]
23. Discovery of antiviral molecules for dengue: In silico search and biological evaluation.
Cabarcas-Montalvo M; Maldonado-Rojas W; Montes-Grajales D; Bertel-Sevilla A; Wagner-Döbler I; Sztajer H; Reck M; Flechas-Alarcon M; Ocazionez R; Olivero-Verbel J
Eur J Med Chem; 2016 Mar; 110():87-97. PubMed ID: 26807547
[TBL] [Abstract][Full Text] [Related]
24. A short survey of dengue protease inhibitor development in the past 6 years (2015-2020) with an emphasis on similarities between DENV and SARS-CoV-2 proteases.
Murtuja S; Shilkar D; Sarkar B; Sinha BN; Jayaprakash V
Bioorg Med Chem; 2021 Nov; 49():116415. PubMed ID: 34601454
[TBL] [Abstract][Full Text] [Related]
25. Identification of Montelukast as flavivirus NS2B-NS3 protease inhibitor by inverse virtual screening and experimental validation.
Jiang H; Zhang Y; Wu Y; Cheng J; Feng S; Wang J; Wang X; Cheng M
Biochem Biophys Res Commun; 2022 May; 606():87-93. PubMed ID: 35339757
[TBL] [Abstract][Full Text] [Related]
26. Piperazine-derived small molecules as potential Flaviviridae NS3 protease inhibitors. In vitro antiviral activity evaluation against Zika and Dengue viruses.
Del Rosario García-Lozano M; Dragoni F; Gallego P; Mazzotta S; López-Gómez A; Boccuto A; Martínez-Cortés C; Rodríguez-Martínez A; Pérez-Sánchez H; Manuel Vega-Pérez J; Antonio Del Campo J; Vicenti I; Vega-Holm M; Iglesias-Guerra F
Bioorg Chem; 2023 Apr; 133():106408. PubMed ID: 36801791
[TBL] [Abstract][Full Text] [Related]
27. Natural DENV-2 NS2B/NS3 protease inhibitors from Myristica cinnamomea King.
Sivasothy Y; Liew SY; Othman MA; Abdul Wahab SM; Hariono M; Mohd Nawi MS; Abdul Wahab H; Awang K
Trop Biomed; 2021 Jun; 38(2):79-84. PubMed ID: 33973577
[TBL] [Abstract][Full Text] [Related]
28. Anthracene-based inhibitors of dengue virus NS2B-NS3 protease.
Tomlinson SM; Watowich SJ
Antiviral Res; 2011 Feb; 89(2):127-35. PubMed ID: 21185332
[TBL] [Abstract][Full Text] [Related]
29. Construction of dengue virus protease expression plasmid and in vitro protease assay for screening antiviral inhibitors.
Lai H; Teramoto T; Padmanabhan R
Methods Mol Biol; 2014; 1138():345-60. PubMed ID: 24696347
[TBL] [Abstract][Full Text] [Related]
30. N-sulfonyl peptide-hybrids as a new class of dengue virus protease inhibitors.
Behrouz S; Kühl N; Klein CD
Eur J Med Chem; 2023 May; 251():115227. PubMed ID: 36893626
[TBL] [Abstract][Full Text] [Related]
31. An Antiviral Peptide from
Ji M; Zhu T; Xing M; Luan N; Mwangi J; Yan X; Mo G; Rong M; Li B; Lai R; Jin L
Toxins (Basel); 2019 Oct; 11(10):. PubMed ID: 31658707
[TBL] [Abstract][Full Text] [Related]
32. Exploiting Dengue Virus Protease as a Therapeutic Target: Current Status, Challenges and Future Avenues.
Mushtaq M; Naz S; Parang K; Ul-Haq Z
Curr Med Chem; 2021; 28(37):7767-7802. PubMed ID: 34212826
[TBL] [Abstract][Full Text] [Related]
33. Novel dengue virus-specific NS2B/NS3 protease inhibitor, BP2109, discovered by a high-throughput screening assay.
Yang CC; Hsieh YC; Lee SJ; Wu SH; Liao CL; Tsao CH; Chao YS; Chern JH; Wu CP; Yueh A
Antimicrob Agents Chemother; 2011 Jan; 55(1):229-38. PubMed ID: 20937790
[TBL] [Abstract][Full Text] [Related]
34. Identification of fused bicyclic derivatives of pyrrolidine and imidazolidinone as dengue virus-2 NS2B-NS3 protease inhibitors.
Weng Z; Shao X; Graf D; Wang C; Klein CD; Wang J; Zhou GC
Eur J Med Chem; 2017 Jan; 125():751-759. PubMed ID: 27721158
[TBL] [Abstract][Full Text] [Related]
35. Effects of NS2B-NS3 protease and furin inhibition on West Nile and Dengue virus replication.
Kouretova J; Hammamy MZ; Epp A; Hardes K; Kallis S; Zhang L; Hilgenfeld R; Bartenschlager R; Steinmetzer T
J Enzyme Inhib Med Chem; 2017 Dec; 32(1):712-721. PubMed ID: 28385094
[TBL] [Abstract][Full Text] [Related]
36. In-silico identification and evaluation of plant flavonoids as dengue NS2B/NS3 protease inhibitors using molecular docking and simulation approach.
Qamar MT; Ashfaq UA; Tusleem K; Mumtaz A; Tariq Q; Goheer A; Ahmed B
Pak J Pharm Sci; 2017 Nov; 30(6):2119-2137. PubMed ID: 29175781
[TBL] [Abstract][Full Text] [Related]
37. Ligand Accessibility Insights to the Dengue Virus NS3-NS2B Protease Assessed by Long-Timescale Molecular Dynamics Simulations.
Kronenberger T; Sá Magalhães Serafim M; Kumar Tonduru A; Gonçalves Maltarollo V; Poso A
ChemMedChem; 2021 Aug; 16(16):2524-2534. PubMed ID: 33899341
[TBL] [Abstract][Full Text] [Related]
38. Boophilin D1, a Kunitz type protease inhibitor, as a source of inhibitors for the ZIKA virus NS2B-NS3 protease.
Manzato VM; Di Santo C; Torquato RJS; Coelho C; Gallo G; Hardy L; Würtele M; Tanaka AS
Biochimie; 2023 Nov; 214(Pt B):96-101. PubMed ID: 37364769
[TBL] [Abstract][Full Text] [Related]
39. Targeting the NS2B-NS3 protease of tick-borne encephalitis virus with pan-flaviviral protease inhibitors.
Akaberi D; Båhlström A; Chinthakindi PK; Nyman T; Sandström A; Järhult JD; Palanisamy N; Lundkvist Å; Lennerstrand J
Antiviral Res; 2021 Jun; 190():105074. PubMed ID: 33872674
[TBL] [Abstract][Full Text] [Related]
40. A Computational Approach Applied to the Study of Potential Allosteric Inhibitors Protease NS2B/NS3 from Dengue Virus.
Costa RAD; Rocha JAPD; Pinheiro AS; Costa ADSSD; Rocha ECMD; Silva RC; Gonçalves ADS; Santos CBR; Brasil DDSB
Molecules; 2022 Jun; 27(13):. PubMed ID: 35807364
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
